Zydus Lifesciences1140.20
+0.00 (+1.38%)

Zydus Lifesciences Share Price

1140.20+0.00 (+1.38%)
+16.67% past 1 Year

Corporate filings & documents

Announcements

Zydus Sunshine Lifesciences signs agreement with Board of Investment Sri Lanka to establish a pharmaceutical manufacturing facility in Sri Lanka.
20 hours ago
Zydus Sunshine Lifesciences signs agreement with Board of Investment Sri Lanka to establish a pharmaceutical manufacturing facility in Sri Lanka.
20 hours ago
USFDA Inspection
2 days ago
USFDA Inspection
2 days ago
Zydus and Formycon: FYB206 Becomes First Publicly Announced Keytruda Biosimilar Accepted for Review by UDFDA.
2 days ago
Zydus and Formycon: FYB206 Becomes First Publicly Announced Keytruda Biosimilar Accepted for Review by UDFDA.
2 days ago
Zydus Therapeutics Presents New Post Hoc Analysis of Phase 3 EPICS-III Trial at ACG 2026 Showing Greater Biochemical Response With Investigational Saroglitazar Compared to Placebo Across Geographic Subgroups in PBC.
3 days ago
Zydus Therapeutics Presents New Post Hoc Analysis of Phase 3 EPICS-III Trial at ACG 2026 Showing Greater Biochemical Response With Investigational Saroglitazar Compared to Placebo Across Geographic Subgroups in PBC.
3 days ago
Certificate under regulation 74(5) of the SEBI (Depositories and Participants) Regulations 2018 for the quarter ended on September 30 2026.
1 week ago
Certificate under regulation 74(5) of the SEBI (Depositories and Participants) Regulations 2018 for the quarter ended on September 30 2026.
1 week ago
Zydus MSN partner to Launch First Generic of Adempas (Riociguat Tablets) in the U.S.
1 week ago
Zydus MSN partner to Launch First Generic of Adempas (Riociguat Tablets) in the U.S.
1 week ago
Extension of date of closing
2 weeks ago
Extension of date of closing
2 weeks ago
USFDA inspection concludes at Zydus manufacturing plant at SEZ II Ahmedabad.
2 weeks ago
USFDA inspection concludes at Zydus manufacturing plant at SEZ II Ahmedabad.
2 weeks ago
Intimation of Trading Window Closure
2 weeks ago
Intimation of Trading Window Closure
2 weeks ago
USFDA inspection of pharmacovigilance and post marketing system concludes at Zydus USA Office with nil observations.
2 weeks ago
USFDA inspection of pharmacovigilance and post marketing system concludes at Zydus USA Office with nil observations.
2 weeks ago
Newspaper publication of Notice of loss of share certificate of the Company published in the Financial Express English and Gujarati editions both on September 24 2026.
3 weeks ago
Newspaper publication of Notice of loss of share certificate of the Company published in the Financial Express English and Gujarati editions both on September 24 2026.
3 weeks ago
Newspaper publication of Notice of opening of Special Window for transfer and dematerialization of physical securities published in the Financial Express English and Gujarati editions both on September 22 2026.
3 weeks ago
Newspaper publication of Notice of opening of Special Window for transfer and dematerialization of physical securities published in the Financial Express English and Gujarati editions both on September 22 2026.
3 weeks ago
Credit Rating
1 month ago
Credit Rating
1 month ago
The Company is going to participate in J.P. Morgan India Conference 2026 on September 21 2026.
1 month ago
The Company is going to participate in J.P. Morgan India Conference 2026 on September 21 2026.
1 month ago
Newspaper publication of Notice of loss of share certificate of the Company published in the Financial Express English and Gujarati editions both on September 9 2026.
1 month ago
Newspaper publication of Notice of loss of share certificate of the Company published in the Financial Express English and Gujarati editions both on September 9 2026.
1 month ago
Settlement Agreement
1 month ago
Settlement Agreement
1 month ago
Transcript of the 31st Annual General Meeting
1 month ago
Transcript of the 31st Annual General Meeting
1 month ago
Zydus Announces Positive Topline Results from Completed EVIDENCES-X Phase II(b) Clinical Trial of Saroglitazar Mg in MASH.
1 month ago
Zydus Announces Positive Topline Results from Completed EVIDENCES-X Phase II(b) Clinical Trial of Saroglitazar Mg in MASH.
1 month ago
Incorporation of a wholly owned subsidiary in Gift City Gandhinagar Gujarat
1 month ago
Incorporation of a wholly owned subsidiary in Gift City Gandhinagar Gujarat
1 month ago
ESG Rating
1 month ago
ESG Rating
1 month ago
Disclosure under SEBI (Prohibition of Insider Trading) Regulations 2015
1 month ago
Disclosure under SEBI (Prohibition of Insider Trading) Regulations 2015
1 month ago
Investor Presentation
1 month ago
Investor Presentation
1 month ago
ESG Rating
1 month ago
ESG Rating
1 month ago
Zydus announces final approval from the USFDA for Ascorbic Acid Injection with 180-Days CGT exclusivity.
1 month ago
Zydus announces final approval from the USFDA for Ascorbic Acid Injection with 180-Days CGT exclusivity.
1 month ago
Transcript of the post results earnings call held on August 11 2026
1 month ago
Transcript of the post results earnings call held on August 11 2026
1 month ago

Concalls & investor presentations

May 2026
Feb 2026
ConcallPresentation
Feb 2026
Nov 2025
ConcallPresentation
May 2021
ConcallPresentation
Feb 2021
ConcallPresentation
Nov 2020
ConcallPresentation

Zydus Lifesciences Ltd Share Price Today

The Zydus Lifesciences Ltd share price today is ₹1152.8. During the trading session, the Zydus Lifesciences Ltd share price opened at ₹1151 and recorded an intraday high of ₹1158 and a low of ₹1123.7. Last closing price was ₹1162. Over the past 52 weeks, the Zydus Lifesciences Ltd share price has ranged between ₹835.5 and ₹1232.1. The current Zydus Lifesciences Ltd stock price reflects real-time market activity based on executed trades on the exchange.